Despite the disappointing ending to Merck's recent HIV vaccine trial, the Partnership for AIDS Vaccine Evaluation (PAVE) is set to start a trial on the next potential vaccine - the PAVE 100 HIV vaccine trial.
The strain is a similar recombinant strain as used in the Merck vaccine, but the criteria for participants is slightly altered, which may aid in determining the effectiveness of the vaccine, but in my opinion, reduce it's generalizability. We'll see.
The AIDS Vaccine Research subcommittee voted 23-3 in favor of beginning the study. The groups responsible for the research are still reviewing the committee's recommendation to determine if they will proceed.
No comments:
Post a Comment